Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 375-381

  Kandula, Sushma ^a   Lamkin, Jeffrey C ^a   Albanese, Teresa ^a   Edward, Deepak P ^a  

^a SUMMA HEALTH SYSTEM   (United States)

Author keywords

Age related macular degeneration; Anti VEGF; Fear of needles; Macular degeneration risk factors; Macular degeneration treatment; Patient education; Ranibizumab

Indexed keywords

VASCULOTROPIN ANTIBODY; VITAMIN;

ADULT; AGED; ARTICLE; ATTITUDE TO ILLNESS; DIETARY INTAKE; EMOTIONALITY; EYE DISCOMFORT; EYE PAIN; FAMILY HISTORY; FEAR; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; KNOWLEDGE; MALE; MEDICAL INFORMATION; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SATISFACTION; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; RISK MANAGEMENT;

EID: 77953415036     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s9969     Document Type: Article

References (41)

1. Friedman DS, O'Colmain B, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
2. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050. Arch Ophthalmol. 2009;127(4): 533-540.
3. US Census Bureau Population Division. National Population Projections, Summary Tables: (NP-T4) Projections of the total resident population by 5-year age groups, race, and Hispanic origin with special age categories:middle series, 1999 to 2100. Washington, DC: U Census Bureau; 2000.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranimizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al. Ranimizumab versus verte-porfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
6. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.
7. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):388-390.
8. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142(1):1-9.
9. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-1058.
10. Clemons TE, Chew EY, Bressler SB, et al. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol. 2003;121(2): 211-217.
11. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
12. Clemons TE, Milton RC, R. Klein, et al. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS): Report No. 19. Ophthalmology. 2005;112(4):533-539.
13. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 1992;110(12):1701-1708.
14. Mitchell P, Wang JJ, Foran S, et al. Five-year incidence of age-related maculopathy lesions: The Blue Mountain Eye Study. Ophthalmology. 2002;109(6):1092-1097.
15. Tan JS, Mitchell P, Kifley A, et al. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol. 2007;125(8):1089-1095.
16. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: A review of association. Eye (Lond). 2005;19(9):935-944.
17. DeAngelis MM, Ji F, Kim IK, et al. Cigarette smoking, CH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125(1):49-54.
18. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006;124(7):995-1001.
19. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 1998;116(12):1646-1651.
20. Klein BE, Klein R, Lee KE, et al. Risk of incident age-related eye disease in people with an affected sibling: The Beaver Dam Eye Study. Am J Epidemiol. 2001;154(3):207-211.
21. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997;123(6):199-206.
22. Schaumberg DA, Hankinson SE, Guo Q, et al. A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol 2007;125(1):55-62.
23. SanGiovanni JP, Chew EY, Clemons TE, et al; Age-Related Eye Disease Study Research Group. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study. AREDS Report No. 20. Arch Ophthalmol. 2007;125(5):671-679.
24. Age-Related Eye Disease Study Research Group, SanGiovanni JP, Chew EY, Clemons TE,et al.The relationship of dietary carotenoids with age-related macular degeneration in a case-control study. AREDS Report No. 22. Arch Ophthalmol. 2007;125(9):1225-1232.
25. Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol. 2000;117(3): 351-358.
26. van Leeuwen R, Ikram MK, Vingerling JR, et al. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44(9):3771-3777.
27. Klein R, Klein BE, Tommy SE, et al. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 2003;110(6):1273-1280.
28. Wright S, Yelland M, Heathcote K, et al. Fear of needles nature and prevalence in general practice. Australian Family Physician. 2009;38(3):172-176.
29. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No.8. Arch Ophthalmol. 2001;119(10):1417-1436.
30. Charkoudian LD, Gower EW, Solomon SD, et al. Vitamin usage patterns in the prevention of age-related macular degeneration. Ophthalmology. 2008;115(6):1032-1038.
31. Klein BE, Knudtson MD, Lee KE, et al. Supplements and age-related eye conditions: the Beaver Dam Study. Ophthalmology. 2008;115(7):1203-1208.
32. Chang CW, Chu G, Hinz BJ, et al. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol. 2003;38(1):27-32.
33. Ng WT, Goggin M. Awareness of and compliance with recommended dietary supplement among age-related macular degeneration patients. Clin Experiment Ophthlmol. 2006;34(1):9-14.
34. van Leeuwen R, Klaver CC, Vingerling JR, et al. Cholesterol and age-related macular degeneration: is there a link? Am J Ophthalmol. 2004;137(4):750-752.
35. Tomany SC, Wang JJ, van Leeuwen R. Risk factors for incident age-related macular degneration: pooled findings from three continents. Ophthalmology. 2004;111(7):1280-1287.
36. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009;25(6):1413-1420.
37. Crockett M, Keystone J. "I hate needles" and other factors impacting on travel vaccine uptake. J Travel Med. 2005;(12 Suppl 1): S41-S46.
38. Dahlin-Ivanoff S, Klepp KI, Sjostrand J, et al. Development of a health education programme for elderly with age-related macular degeneration. Patient Educ Counse. 1998;34(1):63-73.
39. Owsley C, McGwin G, Scilley K, et al. Focus groups with persons who have age-related macular degeneration: Emotional issues. Rehabil Psychol. 2006;51(1):23-29.
40. Michels S, Rosenfeld PJ. Treatment of neovascular age-related macular degeneration with ranibizumab/Lucentis®. Klin Monatsbl Augenheilkd. 2005;222(6):480-484.
41. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials. Br J Ophthalmol. 2010;92(1):2-13.